Juvena Therapeutics Company Research Report

Company Overview

Name

Juvena Therapeutics

Mission

Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to research, develop, and commercialize tissue restorative biologics to treat myopathies and metabolic diseases.

Founding Details

Founded by: Dr. Hanadie Yousef (Co-Founder and CEO) and Dr. Jeremy O’Connell (Co-Founder and CSO)

Key People

Dr. Hanadie Yousef, PhD: Chief Executive Officer and Co-Founder

Dr. Jeremy O’Connell, PhD: Chief Scientific Officer and Co-Founder

Bernard (Barney) D. King, MD, MBA, RAC (US, EU): Chief Medical Officer

Banmeet Anand, PhD: Senior Vice President of Drug Development

Bek Madjidov: Head of Finance and Operations

Headquarters

Located at 640 Galveston Drive, Redwood City, CA 94063

Number of Employees

No information is available

Revenue

No information is available

Known For

Juvena Therapeutics is known for pioneering the therapeutic potential of secreted proteins, specifically in the treatment of muscle and metabolic diseases. They have developed the JuvNET platform for discovering and translating secreted proteins into biologics.

Products

Offered Products

Juvena Therapeutics offers biologic products focusing on tissue restoration and combating muscle and metabolic diseases. A specific focus is on Myotonic Dystrophy Type 1 (DM1), obesity, and sarcopenia.

Product: JUV-161

Description: JUV-161 is an investigational therapeutic protein developed for the treatment of Myotonic Dystrophy Type 1.

Key Features:

Restores muscle fiber formation

Counters muscle atrophy

Enhances muscle strength and endurance

Improves metabolism

Developed to be administered via subcutaneous injection

Recent Developments

Recent Developments in the Company

January 2024: Juvena Therapeutics received FDA Orphan Drug Designation for JUV-161 for Myotonic Dystrophy Type 1.

October 2024: CEO Dr. Hanadie Yousef was nominated to Founders Forum’s "100 Women Founders to Watch".

June 2024: Juvena was selected by the World Economic Forum as part of the 2024 global cohort of "Technology Pioneers".

July 2023: Juvena participated in the Longevity Summit: Ending Age-Related Diseases in NYC.

New Products Launched

No specific new product launches have been detailed aside from the focus and advancement of JUV-161.

New Features Added to Existing Products

No information is available regarding new features added to existing products.

New Partnerships and Collaborations

Juvena partners with the Myotonic Dystrophy Foundation to enhance outcomes for patients with DM1.

Participated in several summits and conferences to discuss innovations, extending their collaborative network, including the Global Healthspan Summit and the Longwood's Boston CEO summit.

Conclusion

Juvena Therapeutics is positioned as a leader in the space of computational biopharmaceutical companies, leveraging artificial intelligence to unlock the therapeutic potential of secreted proteins. With a focus on biologics for chronic and systemic diseases, they continue to make strides in addressing unmet medical needs through innovative platforms and strategic partnerships.